Aditi Singh, MD
Hematology & Oncology · Philadelphia, PANPI 1093072134
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,960 of the $3,037 with a category attached, or 97.5%. E.r. Squibb & Sons, L.L.C. accounts for 97.5% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $2,985, more than ten times the $28 reported in 2022.
Across 4 payments — averaging $759.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$3K
- Beigene USA, Inc.$52
- Novocure Inc.$25
Across 8 payments — averaging $11,519 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$92K
What the payments were for
- Consulting fees$2,96097%
- Food & beverage$773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 1 | $2,960 |
| Beigene USA, Inc. | 2 | $52 |
| Novocure Inc. | 1 | $25 |
How this compares
$3,037 in reported general payments places this provider in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 27 | $429,730 |
| EliquisApixaban | 11 | $10,466 |
| Ondansetron Hcl | 11 | $156 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.